Skip to content
You can now search across every topic, entity and event.What's new
Avego BioScience Capital
OrganisationUS

Avego BioScience Capital

Biotech investment vehicle; participated in CellCentric's £170m Series D.

Last refreshed: 13 May 2026

Timeline for Avego BioScience Capital

View full timeline →
Common Questions
What is Avego BioScience Capital?
Avego BioScience Capital is a biotech investment vehicle that participated in CellCentric's £170m Series D in May 2026. It has a limited public profile with no confirmed prior press coverage.Source: Lowdown uk-startups-and-innovation U#4
Who invested in CellCentric's £170m biotech round?
CellCentric's Series D was led by Venrock Healthcare Capital Partners and included Pfizer, Fidelity, Sofinnova Partners, HBM Healthcare, RA Capital Management, the American Cancer Society BrightEdge, and Avego BioScience Capital.Source: Lowdown uk-startups-and-innovation U#4

Background

Avego BioScience Capital participated in CellCentric's £170m Series D in May 2026 alongside lead Venrock Healthcare Capital Partners, Pfizer, Fidelity, and a range of life-sciences specialist investors. CellCentric is advancing inobrodib through a Phase III programme in multiple myeloma and prostate cancer.

Avego BioScience Capital has a limited public profile as of May 2026. The name and participation pattern are consistent with a specialist biotech investment vehicle, but no public filings, website, or prior press coverage can be confirmed in available sources. Given the co-investor quality in the CellCentric round — which includes Venrock, Fidelity, and Pfizer — Avego's presence is consistent with an institutional vehicle with biotech sector expertise, rather than an opportunistic position. Future enrichment should be triggered if public registration or further deal announcements clarify its mandate.